Released May 7, 2026, after the close
10-Q filed May 7, 2026, 37 days after period end · 0001785530-26-000012
Q1 2026 · 10-Q
Revenue—
Net Income-$13.53M-$13.53M N/M vs Q1 2025N/M vs Q4 2025
EPS Diluted-$0.28-$0.28 N/M vs Q1 2025no prior Q4 2025 on file
Operating Income-$13,271,000N/M
Operating Cash Flow-$10,597,000N/M
What the release said
The release
Same quarter
| Metric | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|---|
| Net Income | -$13.53M | -$18.09M | -$16.19M | -$11.98M |
| EPS Diluted | -$0.28 | -$0.40 | -$0.39 | -$0.34 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Werewolf Therapeutics, Inc. · CIK 1785530 · Engraved from SEC EDGAR